ArticlePharmacology2023

Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.

Young Ho Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.